

09/900, 147

WEST

Freeform Search

Database:

Term:

Display: Documents in **Display Format:** Starting with Number

Generate: Hit List Hit Count Side by Side Image

Search History

DATE: Monday, December 16, 2002 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
<u>L3</u>	L2 and e2f protein	12	<u>L3</u>
<u>L2</u>	dp protein	28	<u>L2</u>
<u>L1</u>	dp-1	231	<u>L1</u>

END OF SEARCH HISTORY

WEST

 [Generate Collection](#) [Print](#)

L3: Entry 1 of 12

File: USPT

Sep 10, 2002

US-PAT-NO: 6448376

DOCUMENT-IDENTIFIER: US 6448376 B1

TITLE: Transcription factor-E2F-5

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas B.	London			GB
Bernards; Rene	Amsterdam			NL
Hijmans; Eleonore M.	Amsterdam			NL

US-CL-CURRENT: 530/350; 435/4, 530/300, 530/324

CLAIMS:

What is claimed is:

1. An isolated E2F-5 polypeptide selected from the group of: the polypeptide comprising SEQ ID NO:2; the polypeptide comprising SEQ ID NO:4; a polypeptide comprising a fragment of SEQ ID NO:2 of at least 60 amino acids, said fragment being capable of forming a transactivation complex with a DP protein; and a polypeptide comprising a fragment of SEQ ID NO:4 of at least 60 amino acids, said fragment being capable of forming a transactivation complex with a DP protein.
2. An isolated polypeptide comprising SEQ ID NO:2.
3. An isolated polypeptide comprising SEQ ID NO:4.
4. An Isolated polypeptide comprising a fragment of at least 60 amino acids of the isolated polypeptide of claim 2 or 3 said fragment being capable of forming a transactivation complex with a DP protein.
5. The isolated polypeptide of claim 1 that is detectably labeled.
6. The isolated polypeptide of claim 1 fixed to a solid phase.
7. A composition comprising the polypeptide according to claim 1 together with a carrier or diluent.
8. A screening assay for identifying an inhibitor of E2F-5/DP complex formation, which assay comprises: bringing into contact: (i) a DP polypeptide, said DP polypeptide being a component of an E2F transcription factor; (ii) the E2F-5 polypeptide of claim 1; and (iii) a putative inhibitor; under conditions in which the components (i) and (ii) in the absence of said putative inhibitor are able to form a complex; and determining the extent to which, if any, the presence of said putative inhibitor is able to disrupt the formation of the complex.
9. The screening assay of claim 8 wherein said determining is made by examining the ability of said complex to bind or activate an E2F DNA binding site in vitro.

10. The screening assay of claim 8 wherein the putative inhibitor is a fragment of 10 or more amino acids of the polypeptide of claim 2.
11. An assay according to claim 8 which further comprises selecting as an inhibitor of E2F-5/DP complex formation a compound capable of so disrupting said complex formation.

WEST

 Generate Collection Print

app # 09/308,935

L3: Entry 6 of 12

different SEQ ID
protein

File: USPT

Jul 31, 2001

US-PAT-NO: 6268334

DOCUMENT-IDENTIFIER: US 6268334 B1

TITLE: Peptide antagonists of DP transcription factors

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
La Thangue; Nicholas B.	Glasgow			GB
Bandara; Lasantha R.	Abingdon			GB

US-CL-CURRENT: 514/2; 530/300

CLAIMS:

What is claimed is:

1. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F.
2. The stent of claim 1 wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.
3. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.
4. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.
5. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer, wherein said polypeptide is fused at its N- or C-terminus to a membrane translocation sequence.
6. The stent of claim 5 wherein said membrane translocation sequence is derived from the *Drosophila melanogaster* *antennapedia* protein.
7. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 and, from 0 to 5 amino acids at the N- or C-terminus, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer.
8. The stent of claim 7, wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

9. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

10. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

US-PAT-NO: 5863757

DOCUMENT-IDENTIFIER: US 5863757 A

TITLE: Transcription factor DP-1

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY
STATE ZIP CODE COUNTRY	
La Thangue; Nicholas Barrie	London
N/A GB	N/A

US-CL-CURRENT: 435/69.1, 435/320.1, 435/325, 536/23.5,
536/24.31

CLAIMS:

I claim:

1. An isolated polynucleotide which comprises the sequence of SEQ ID NO:1 or its complement.
2. The polynucleotide of claim 1 which is a DNA polynucleotide.
3. A double stranded polynucleotide comprising a polynucleotide according to claim 1 and its complement.
4. A replicable vector which comprises a polynucleotide according to claim 1.
5. A host cell comprising a vector according to claim 4.
6. An isolated polynucleotide which comprises a fragment of at least 15 nucleotides of the polynucleotide of SEQ ID NO:1 or its complement.

7. The isolated polynucleotide of claim 6 which comprises at least 40 nucleotides of the polynucleotide of SEQ ID NO:1 or its complement.

8. The isolated polynucleotide of claim 6 which comprises the open reading frame of SEQ ID NO:1.

9. The isolated polynucleotide of claim 8 which is a DNA polynucleotide.

10. A replicable vector which comprises a polynucleotide according to claim 8.

11. A host cell comprising a vector according to claim 10.

12. An isolated polynucleotide which comprises a contiguous sequence of nucleotides having at least 80% homology to at least 40 contiguous nucleotides of SEQ ID NO:1.

13. The isolated polynucleotide of claim 12 which encodes the polypeptide as set out in SEQ ID NO:2.

14. The isolated polynucleotide of claim 12 which encodes a peptide sequence as set out as residues 160-220 of SEQ ID NO:2.

15. The isolated polynucleotide of claim 12 which is a DNA polynucleotide.

16. A replicable vector which comprises a polynucleotide according to claim 12.

17. A host cell comprising a vector according to claim 12.

18. An expression vector which comprises polynucleotide having an open reading frame operably linked to a promoter, said open reading frame encoding a polypeptide selected from the group consisting of:

- (a) the polypeptide of SEQ ID NO:2;
- (b) an allelic variant or mammalian homologue of SEQ ID NO:2;
- (c) a polypeptide having at least 70% homology over at least 20 amino acids to SEQ ID NO:2;
- (d) a fragment of any one of (a) to (c) capable of forming a complex with the E2F-1 protein; and
- (e) a fragment of any one of (a) to (c) of at least 15 amino acids.

19. A host cell transformed by the expression vector of claim 18.

20. A process for preparing a polypeptide encoded by the expression vector of claim 18 which process comprises cultivating a host cell transformed by said expression vector under conditions to provide for expression by said vector of the open reading frame, and recovering the expressed polypeptide.

US-PAT-NO:

6268334

Not double patenting

DOCUMENT-IDENTIFIER: US 6268334 B1

TITLE: Peptide antagonists of DP
transcription factors

DATE-ISSUED: July 31, 2001

INVENTOR-INFORMATION:

NAME	CITY	
STATE ZIP CODE COUNTRY		
La Thangue; Nicholas B. N/A GB	Glasgow	N/A
Bandara; Lasantha R. N/A GB	Abingdon	N/A

US-CL-CURRENT: 514/2, 530/300

CLAIMS:

What is claimed is:

1. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F.

2. The stent of claim 1 wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

3. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

4. The stent of claim 1 wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

5. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer, wherein said polypeptide is fused at its N- or C-terminus to a membrane translocation sequence.

6. The stent of claim 5 wherein said membrane translocation sequence is derived from the *Drosophila melanogaster* antennapedia protein.


7. A surgical stent which comprises a coating incorporating a polypeptide in a pharmaceutically acceptable carrier, the polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 and, from 0 to 5 amino acids at the N- or C-terminus, or a variant thereof having from 1 to 5 amino acid substitutions, the variant retaining the ability to antagonize the formation of a DP/E2F heterodimer.

8. The stent of claim 7, wherein said variant includes a substitution selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

9. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 15.

10. The stent of claim 7, wherein said variant consists of the amino acid sequence of SEQ ID NO: 16.

09/900, 147



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	B
Search <input type="text" value="PubMed"/> <input type="checkbox"/> for <input type="text"/>				Preview <input type="button" value="Go"/> <input type="button" value="Clear"/>				
Limits Preview/Index History				Clipboard Details				

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Browser](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[Cubby](#)

[Related Resources](#)

[Order Documents](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[Privacy Policy](#)

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#13	Related Articles for PubMed (Select 8989145)	14:12:06	122
#11	Search circulation[jour] AND 94[volume] AND 3311[page] Field: Title Word	14:10:40	1
#9	Related Articles for PubMed (Select 10922232)	13:26:04	155
#5	Related Articles for PubMed (Select 9440847)	13:09:49	184
#3	Search j endourol[jour] AND 11[volume] AND 399[page] Field: Title Word	13:06:11	1
#1	Search stent AND peptides	13:03:49	164

[Clear History](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Dec 13 2002 14:22:59

09/900, 187

WEST

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show S Numbers](#) | [Edit S Numbers](#) | [Preferences](#) | [Cases](#)**Search Results -**

Term	Documents
E2F	359
E2FS	14
PROTEIN	116330
PROTEINS	94589
@PD	7087668
((2 AND (E2F ADJ PROTEIN)) AND ((@PD > "20021216")!)).USPT.	0
((L2 AND E2F PROTEIN) AND ((@PD > 20021216)!)).USPT.	0

Database:

Search:

Search History

DATE: Monday, June 09, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query
side by side

Hit Count Set Name
result set

DB=USPT; THES=ASSIGNEE; PLUR=YES; OP=ADJ

<u>L3</u>	(L2 and e2f protein) AnD ((@pd > 20021216)!)	0	<u>L3</u>
<u>L2</u>	(dp protein) AnD ((@pd > 20021216)!)	2	<u>L2</u>
<u>L1</u>	(dp-1) AnD ((@pd > 20021216)!)	6	<u>L1</u>

END OF SEARCH HISTORY